View Item 

Show simple item record

A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease
dc.contributor.authorLawlor, Brian A.en_US
dc.contributor.authorSunderland, Treyen_US
dc.contributor.authorMellow, Alan M.en_US
dc.contributor.authorMolchan, Susan E.en_US
dc.contributor.authorMartinez, Rick A.en_US
dc.contributor.authorMurphy, Dennis L.en_US
dc.date.accessioned2006-04-10T14:39:03Z
dc.date.available2006-04-10T14:39:03Z
dc.date.issued1991-07-15en_US
dc.identifier.citationLawlor, Brian A., Sunderland, Trey, Mellow, Alan M., Molchan, Susan E., Martinez, Rick, Murphy, Dennis L. (1991/07/15)."A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease." Biological Psychiatry 30(2): 140-144. <http://hdl.handle.net/2027.42/29223>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6T4S-484N6PS-9R/2/e8a181be296f5b9c3c9e0b586f43a432en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/29223
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1912105&dopt=citationen_US
dc.description.abstractMeta000000-Chlorophenylpiperazine (m-CPP), a serotonin agonist and metabolite of the anti-depressant trazodone, was administered chronically to eight moderate to severely affected Alzheimer patients to determine whether it would produce improvement in behavioral symptoms complicating this illness. In doses up to 80 mg/day for 16 days, m-CPP was well tolerated and resulted in small but significant increases in anergy and depression-related symptoms compared with placebo. The effects of chronic m-CPP in this study contrast with the reported beneficial effects of the parent compound trazodone and selective 5-HT reuptake inhibitors in treating behavioral symptoms in Alzheimer patients.en_US
dc.format.extent655937 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleA pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDivision of Geriatric Psychiatry, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USAen_US
dc.contributor.affiliationotherLaboratory of Clinical Science, Bethesda, MD, USAen_US
dc.contributor.affiliationotherLaboratory of Clinical Science, Bethesda, MD, USAen_US
dc.contributor.affiliationotherLaboratory of Clinical Science, Bethesda, MD, USAen_US
dc.contributor.affiliationotherLaboratory of Clinical Science, Bethesda, MD, USAen_US
dc.identifier.pmid1912105en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/29223/1/0000278.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0006-3223(91)90167-Ken_US
dc.identifier.sourceBiological Psychiatryen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0000278.pdf
Size:
640.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.